, a leader in the advancement of therapeutics for the treatment of pain, and the company’s wholly possessed subsidiary, PharmaForm, announced its financial outcomes for the 90 days and year finished December 31 today, 2010. December 31 Total consolidated revenues for the three months ended, 2010 were $3.7 million, including $3.0 million of contract services, when compared with $3.0 million, including $2.4 million of contract companies, for the same period during the prior year.3 million, including $10.2 million of contract companies, when compared with $13.9 million, including $10.6 million of contract services, for 2009. December 31 Consolidated net income for the three and twelve months ended, 2010 had been $1.5 million, $0.05 per share, and $1.2 million, $0.04 per share, versus losses of $14.1 million, per talk about, and losses of $21.0 million, per share, for the same respective periods in 2009 2009.Dr. Haythornthwaite’s scientific contributions have got focused on the study of psychosocial areas of pain, specially the impact of bad emotions and pain-coping strategies on pain and pain-related disability. Her recent function has examined the impact of negative feelings and pain-coping strategies on neuropathic discomfort. Dr. Haythornthwaite’s current research projects are focused on developing innovative remedies for reducing catastrophizing and investigating biobehavioral factors that boost risk for persistent discomfort. She has served in several leadership positions for the American Pain Society, including provider on the Panel of Directors. The Frederick W.L. Kerr Basic Science Study Award honors individual excellence and achievements in scientific discomfort scholarship and is named honoring the founder of APS, Frederick W.L.